Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
0(0%)
Results Posted
42%(5 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_2
4
29%
Ph not_applicable
2
14%
Ph phase_1
7
50%
Ph early_phase_1
1
7%

Phase Distribution

8

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution14 total trials
Early Phase 1First-in-human
1(7.1%)
Phase 1Safety & dosage
7(50.0%)
Phase 2Efficacy & side effects
4(28.6%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(12)
Terminated(2)

Detailed Status

Completed12
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (7.1%)
Phase 17 (50.0%)
Phase 24 (28.6%)
N/A2 (14.3%)

Trials by Status

terminated214%
completed1286%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

NCT02005289
completedphase_2

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT01652196
completedphase_1

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222
completedearly_phase_1

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT02013492
terminatednot_applicable

Central Pain Syndrome in Survivors of Head and Neck Cancer

NCT04128267
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT02005289Phase 2

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Completed
NCT01652196Phase 2

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Completed
NCT02120222Phase 1

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Completed
NCT02013492Early Phase 1

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Completed
NCT04128267Not Applicable

Central Pain Syndrome in Survivors of Head and Neck Cancer

Terminated
NCT02049541Phase 1

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Completed
NCT02144649Not Applicable

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

Completed
NCT01064921Phase 1

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

Completed
NCT01713972Phase 1

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Completed
NCT02035527Phase 1

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
NCT00824733Phase 2

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Terminated
NCT00561418Phase 1

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Completed
NCT00201773Phase 2

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Completed
NCT01129180Phase 1

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Completed

All 14 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
14